Same exact drug. Different label, different dose, different insurance code. Welcome to pharma branding.
Bottom line: This is the same molecule in different packaging. The drug in your body does not know which box it came from. The real difference is the label (diabetes vs weight loss), the max dose (2.0 mg vs 2.4–7.2 mg), and insurance coverage. If your insurance covers one but not the other, that is your answer. If you are paying out of pocket, compounded semaglutide from a vial is the same molecule at a fraction of the cost.
| Ozempic | Wegovy | |
|---|---|---|
| Category | GLP-1 receptor agonist (diabetes indication) | GLP-1 receptor agonist (weight management indication) |
| Mechanism | Semaglutide — identical molecule, same mechanism in both products | Semaglutide — identical molecule, same mechanism in both products |
| Reported dose | 0.25 mg, 0.5 mg, 1.0 mg, or 2.0 mg weekly | 0.25 mg titrating up to 2.4 mg weekly (injection); Wegovy HD approved at 7.2 mg (March 2026) |
| Frequency | Once weekly injection | Once weekly injection |
| Weight loss (trials) | ~6–10% (studied at diabetes doses, max 2.0 mg) | ~15% at 68 weeks (STEP 1, 2.4 mg dose) |
| Top side effect | Nausea, vomiting, diarrhea — same drug, same side effects | Nausea, vomiting, diarrhea — higher max dose may mean more GI symptoms |
| Evidence tier | Tier 1 — approved 2017, massive real-world safety database | Tier 1 — approved 2021, STEP trial program, cardiovascular benefit data (SELECT trial) |
| Common vial size | Pre-filled multi-dose pen (1.5 ml or 3 ml) | Pre-filled single-dose pen (0.5 ml per pen) |
| Approval status | FDA-approved for type 2 diabetes (2017) | FDA-approved for chronic weight management (2021), cardiovascular risk reduction |
Ozempic makes sense if you have type 2 diabetes (it is indicated for this), if your insurance covers diabetes meds but not weight loss drugs, or if you are comfortable at the 2.0 mg max dose. Many doctors prescribe Ozempic off-label for weight loss because insurance coverage is better.
Wegovy is the technically correct choice if weight management is your primary goal. It goes to 2.4 mg (and now 7.2 mg with Wegovy HD), has specific weight loss trial data, and the SELECT trial showed cardiovascular benefit in non-diabetic obese patients. Insurance coverage for obesity indication is improving.
This is the same molecule in different packaging. The drug in your body does not know which box it came from. The real difference is the label (diabetes vs weight loss), the max dose (2.0 mg vs 2.4–7.2 mg), and insurance coverage. If your insurance covers one but not the other, that is your answer. If you are paying out of pocket, compounded semaglutide from a vial is the same molecule at a fraction of the cost.
← Browse all peptides | All comparisons →
vialprep research · Sources: PubMed, FDA, peer-reviewed trials · How we verify